Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Revenue increased by ¥1,130 million due to strong performance from the イズカーゴ product and higher contract fee income, while research and development expenses increased by ¥2,540 million due to the progress of global clinical development.
Not applicable (no matters to report in the notes on the going concern assumption)
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥9,700 million (YoY +13.2%) |
| Operating profit | ¥-2,103 million |
| Ordinary income | ¥-2,084 million |
| Profit attributable to owners of the parent | ¥-1,907 million |
| Net income per share | -¥15.64 |
| Equity ratio | End of the current fiscal period 40.6 / End of previous period 42.9 |
| Total assets | ¥106,400 million |
| Net assets | ¥43,632 million |
| Full-year earnings forecast | Net Sales ¥45,700 million (YoY +13.3%) / Operating profit ¥1,100 million (YoY +98.2%) / Ordinary income ¥500 million (YoY -57.1%) / Net income ¥200 million (YoY -90.8%) |
| Annual Dividend Forecast | 20 yen and sen → 20 yen and sen（0.0%） |
| Depreciation and amortization | ¥517 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Item Losses on disposal of fixed assets / Amount ¥0 million |
| Disclosure regarding the going concern assumption | Not applicable (no matters to report in the notes on the going concern assumption) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Name of newly added company Not disclosed / Excluded 0 / Excluded Company Name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 129,686,308 Shares |
| Treasury Shares at Period-End | 7,656,978 Shares |
| Factors Behind Changes in Business Performance | Revenue increased by ¥1,130 million due to strong performance from the イズカーゴ product and higher contract fee income, while research and development expenses increased by ¥2,540 million due to the progress of global clinical development. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The イズカーゴ product performed strongly and contract fee income increased, while research and development expenses rose by ¥2,540 million as a result of active R&D activities accompanying the progress of global clinical development. Revenue from グロウジェクト decreased.